7S5Q

Crystal structure of SARS-CoV-2 B.1.351 variant receptor binding domain in complex with neutralizing antibodies CS44 and COVA1-16

Summary for 7S5Q

• Entry DOI: 10.2210/pdb7s5q/pdb
• Descriptor: Spike protein S1, CS44 Heavy chain, CS44 Light chain, ... (9 entities in total)
• Functional Keywords: sars-cov-2, coronavirus, antibody, fab, voc, beta, b.1.351, spike, rbd, immune system, viral protein-immune system complex, viral protein/immune system
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV, SARS-CoV-2); More
• Total number of polymer chains: 5
• Total formula weight: 123688.44

Authors

Yuan, M.,Wilson, I.A. (deposition date: 2021-09-11, release date: 2022-03-09, Last modification date: 2023-10-18)

Primary citation

Reincke, S.M.,Yuan, M.,Kornau, H.C.,Corman, V.M.,van Hoof, S.,Sanchez-Sendin, E.,Ramberger, M.,Yu, W.,Hua, Y.,Tien, H.,Schmidt, M.L.,Schwarz, T.,Jeworowski, L.M.,Brandl, S.E.,Rasmussen, H.F.,Homeyer, M.A.,Stoffler, L.,Barner, M.,Kunkel, D.,Huo, S.,Horler, J.,von Wardenburg, N.,Kroidl, I.,Eser, T.M.,Wieser, A.,Geldmacher, C.,Hoelscher, M.,Ganzer, H.,Weiss, G.,Schmitz, D.,Drosten, C.,Pruss, H.,Wilson, I.A.,Kreye, J.
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies.
Science, 375:782-787, 2022

PubMed Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type-elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.

PubMed: 35076281
DOI: 10.1126/science.abm5835

Experimental method

X-RAY DIFFRACTION (2.88 Å)